4 stories mentioning HKG:0460
Every FINWIRES story that references HKG:0460, newest first.
Sihuan Pharmaceutical's (HKG:0460) trustee bought back 8 million shares of the firm from the market for around HK$1.0052 apiece under a 2022 share award scheme, according to a Wednesday filing with the Hong Kong bourse.The company's shares fell nearly 4% in late morning trade Thursday.The shares represent 0.0877% of the pharma firm's issued share capital.
Sihuan Pharmaceutical's (HKG:0460) trustee bought back 3 million shares of the firm from the market for around HK$1.3567 apiece under a 2022 share award scheme, according to a Tuesday filing with the Hong Kong bourse.The shares represent 0.0328% of the pharma firm's issued share capital.
Sihuan Pharmaceutical Holdings Group (HKG:0460) said a drug developed by its non wholly-owned subsidiary Xuanzhu Biopharmaceutical (HKG:2575) was found to benefit patients with lung cancer in a late-stage study, according to a Hong Kong bourse filing Monday.Results from the phase 3 clinical trial showed that dirozalkib demonstrated "statistically and clinically significant efficacy advantages" in the first-line treatment of ALK-positive advanced non-small cell lung cancer.In the modified intention-to-treat population, the drug was found to have achieved a median progression-free survival of 31.3 months compared with 12.9 months in the control group.The drug's objective response rate stood at 88.5% with a median duration of response of 32.10 months and a disease control rate of 95.4%.The firm presented the trial results at the 2026 American Association for Cancer Research annual meeting.
Xuanzhu Biopharmaceutical (HKG:2575) received approval in China to initiate a phase 3 clinical trial of anaprazole sodium, according to a Wednesday Hong Kong bourse filing by parent Sihuan Pharmaceutical (HKG:0460).The trial will evaluate the drug as part of a bismuth-containing quadruple therapy for the eradication of Helicobacter pylori infection, and plans to enroll 556 adult patients.